Company intelligence / Profile preview
Ambrosia Biosciences
Boulder, Colorado, United Statesambrosiabiosciences.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Preclinical
01
Overview
The company is still in early development stages with plans to present first preclinical data sets near the end of 2025 and file its first investigational new drug application with the FDA around the end of 2026[2].
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Ambrosia Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambrosia Biosciences.